EC
GLUE icon

EcoR1 Capital’s Monte Rosa Therapeutics GLUE Stock Holding History

EcoR1 Capital’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-37,593
Closed -$768K – 90
2021
Q4 		$768K Buy
+37,593
New +$787K 0.02% 68

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

EcoR1 Capital's GLUE Position: Q1 2022 in Review

EcoR1 Capital sold out of Monte Rosa Therapeutics (GLUE) in Q1 2022, closing a stake of 37,593 shares — an estimated $768K sold.

EcoR1 Capital first reported a position in GLUE in Q4 2021 and held it in 1 quarter. The position peaked at $768K in Q4 2021. 52 funds tracked by Wall St. Rank hold GLUE as of Q1 2022.

  • EcoR1 Capital reported no remaining Monte Rosa Therapeutics position as of Q1 2022 after selling out during the quarter.
  • EcoR1 Capital sold 37,593 Monte Rosa Therapeutics shares in Q1 2022, an estimated $768K.
  • EcoR1 Capital first reported a position in Monte Rosa Therapeutics in Q4 2021 and held it in 1 quarter.
  • EcoR1 Capital's Monte Rosa Therapeutics position peaked at $768K in Q4 2021.
  • 52 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2022.

Based on EcoR1 Capital's 13F filing for Q1 2022, filed 16 May 2022.